Company Focus
Roche
Latest Roche News
Pharmaceutical
German pharma and crop science major Bayer posted second-quarter 2026 sales of 10.87 billion euros ($12.39 billion), up 1.2% as reported and 2.2% on a currency- and portfolio-adjusted basis. Core earnings per share fell 16.7% to 0.95 euros ($1.08), held back by a normalization in tax expense and weaker earnings in the group's reconciliation line. 4 August 2026
Related News
Insights
Company Spotlight
A Vancouver-based clinical-stage biotechnology company that combines single-cell screening, microfluidics and AI to discover and develop antibody therapeutics across oncology and immunology, while holding downstream stakes in 40 partner-led programs.
Latest News & Features of interest to Roche
Pharmaceutical
Tenax Therapeutics saw its shares plummet 90% to $1.38, after it announced disappointing top-line results from the Phase III LEVEL clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension (PH)- preserved ejection fraction (HFpEF). 11 August 2026
Pharmaceutical
Privately-held German biopharma company Isotope Technologies Munich (ITM) revealed that it has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application for 177Lu-edotreotide (ITM-11), an investigational agent for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 11 August 2026
Biotechnology
London-based biotech firm Silence Therapeutics said on Monday that lead candidate divesiran met the primary endpoint of the Phase II SANRECO trial in polycythemia vera (PV), a rare blood cancer in which the bone marrow overproduces red blood cells. Shares rose sharply on the news, touching a 52-week high. 11 August 2026
Biotechnology
Privately-held US biotech Avere Therapeutics, which is advancing oral therapies for interleukin (IL)-23 driven inflammatory diseases, has announced a $500 million private placement from a syndicate of leading healthcare investors. 11 August 2026
Pharmaceutical
Donald Trump signed an executive order on Monday recommending that American children be routinely immunized against 11 diseases rather than the 18 covered by the US Centers for Disease Control and Prevention's (CDC) 2024 schedule, and that the combined measles, mumps and rubella (MMR) vaccine be split into three single-disease shots. 11 August 2026
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire privately-held US biotech Actio Biosciences with the aim of expanding its epilepsy portfolio. 10 August 2026
Biotechnology
Shares of Canada’s AbCellera were up nearly 33% at $9.20 in pre-market activity today after it announced positive top-line results from the Phase II portion of its Phase I/II clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody. 10 August 2026
Biotechnology
French rare diseases company Innate Pharma (and Swedish Orphan Biovitrum (Sobi) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase III study in cutaneous T-cell lymphoma (CTCL). 10 August 2026
Pharmaceutical
Danish-based, Swedish-listed biotech Saniona (OMX: SANION) said today that its UK partner AstronauTx has exercised an option to take exclusive worldwide rights to compounds emerging from the pair's ion channel collaboration, handing Saniona equity worth $5 million and keeping alive a milestone package of up to $172 million. 10 August 2026
Biotechnology
Japanese pharmaceutical company Eisai has officially launched Leqembi (lecanemab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). 10 August 2026
Latest In Brief for Roche
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze